REFERENCES

• American Psychiatrie Association.Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association;1994
   Google Scholar
• National Institute of Mental Health Anxiety Disorders Research at the National Institute of Mental Health, December 7, 2002 Available at: http://www.nimh. nih.gov/publicat/anxresfact.cfm. Accessed June 12, 2003.
   Google Scholar
• American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association;1980
   Google Scholar
• World Health Organization.The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization;1992
   Google Scholar
• KesslerRC.WittchenHU.Patterns and correlates of generalized anxiety disorder in community samples.J Clin Psychiatry.200263(suppl 8)41012044107
   PubMed Web of Science ®Google Scholar
• SheltonRC.BrownLL.Mechanisms of action in the treatment of anxiety.J Clin Psychia try.200162(suppl 12)1015
   PubMed Web of Science ®Google Scholar
• NuttDJ.BallengerJC.SheehanD.WittchenHU.Generalized anxiety disorder: comorbidity, comparative biology and treatment.Int J Neuropsychopharmacol.2002531532512466031
   PubMed Web of Science ®Google Scholar
• ShaderRl.GreenblattDJ.Drug therapy Benzodiazepines.N Engl J Med.1974291101110154153318
   PubMed Web of Science ®Google Scholar
• ShaderRl.GreenblattDJ.Drug therapy Benzodiazepines.N Engl J Med.1974291123912434153568
   PubMed Web of Science ®Google Scholar
• WittchenHU.KesslerRC.BeesdoK.KrauseP.HoflerM.HoyerJ.Generalized anxiety and depression in primary care: prevalence, recognition, and management.J Clin Psychiatry.200263(suppl 8)243412044105
   PubMed Web of Science ®Google Scholar
• JacobiF.WittchenHU.HoltingC.et al.Estimating the prevalence of mental and somatic disorders in the community: aims and methods of the German National Health Interview and Examination Survey,.Int J Methods Psychiatr Res.20021111812459800
   PubMed Web of Science ®Google Scholar
• RiceDP.MillerLS.Health economics and cost implications of anxiety and other mental disorders in the United States.Br J Psychiatry Suppl.1998499829010
   PubMedGoogle Scholar
• HouseA.StarkD.Anxiety in medical patients.BMJ.200232520720912142312
   PubMedGoogle Scholar
• WittchenHU.KrauseP.HoyerJ.et al.Prevalence and correlates of generalized anxiety disorders in primary care [in German].Fortschr Med Orig.2001119(suppl 1)172511935664
   PubMedGoogle Scholar
• CulpepperL.Generalized anxiety disorder in primary care: emerging issues in management and treatment.J Clin Psychiatry.200263(suppl 8)354212044106
   PubMedGoogle Scholar
• HollisterLE.Müller-OerlinghausenB.RickelsK.ShaderRl.Clinical uses of benzodiazepines.J Clin Psychopharrnacol.199313(suppl 1)1S169S
   Web of Science ®Google Scholar
• ShaderRl.GreenblattDJ.Use of benzodiazepines in anxiety disorders.N Engl J Med.1993328139814058292115
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.ShaderRl.AbernethyDR.Drug therapy. Current status of benzodiazepines.N Engl J Med.19833093543586135156
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.ShaderRl.AbernethyDR.Drug therapy. Current status of benzodiazepines.N Engl J Med.19833094104166135990
   PubMed Web of Science ®Google Scholar
• MöllerHJ.Effectiveness and safety of benzodiazepines.J Clin Psychopharrnacol.199919(suppl 2)2S11S
   Web of Science ®Google Scholar
• UhlenhuthEH.BaiterMB.BanTA.YangK.International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. V. Treatment strategies in panic disorder, 1992-1997.J Clin Psychopharrnacol.199818(suppl 2)27S31S
   Web of Science ®Google Scholar
• LaderMH.Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?.Eur Neuropsychopharmacol.1999(suppl 6)S399S40510622686
   PubMedGoogle Scholar
• WoodsJH.KatzJL.WingerG.Abuse liability of benzodiazepines.Pharmacol Rev.1987392514132893392
   PubMed Web of Science ®Google Scholar
• WoodsJH.KatzJL.WingerG.Use and abuse of benzodiazepines. Issues relevant to prescribing.JAMA.1988260347634803062199
   PubMed Web of Science ®Google Scholar
• WoodsJH.KatzJL.WingerG.Benzodiazepines: use, abuse, and consequences.Pharmacol Rev.1992441513471356276
   PubMed Web of Science ®Google Scholar
• WoodsJH.Problems and opportunities in regulation of benzodiazepines.J Clin Pharmacol.1998387737829753204
   PubMed Web of Science ®Google Scholar
• ShaderRl.GreenblattDJ.BaiterMB.Appropriate use and regulatory control of benzodiazepines.J Clin Pharmacol.1991317817841687147
   PubMed Web of Science ®Google Scholar
• NinanPT.New insights into the diagnosis and pharmacologic management of generalized anxiety disorder.Psychopharrnacol Bull.200236105122
   PubMedGoogle Scholar
• GormanJM.Treatment of generalized anxiety disorder.J Clin Psychiatry.200263(suppl8)172312044104
   PubMedGoogle Scholar
• KapczinskiF.SchmittR.LimaMS.The use of antidepressants for generalized anxiety disorder.The Cochrane Library. 2002 (Issue 2). Oxford, UK: Update Software.
   Google Scholar
• KasperS.ResingerE.Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors.Eur Neuropsychopharmacol.20011130732111532386
   PubMed Web of Science ®Google Scholar
• MasandPS.GuptaS.Selective serotonin-reuptake inhibitors: an update.Harv Rev Psychiatry.19997698410471245
   PubMed Web of Science ®Google Scholar
• MahmoodI.SahajwallaC.Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.Clin Pharmacokinet.19993627728710320950
   PubMed Web of Science ®Google Scholar
• FultonB.BrogdenRN.Buspirone: an updated version of its clinical pharmacology and therapeutic applications.CNS Drugs.199776888
   Web of Science ®Google Scholar
• PittlerMH.ErnstE.Kava extract for treating anxiety.Cochrane Database Syst Rev. 2003:CD003383.
   Google Scholar
• BiliaAR.GallonS.VincieriFF.Kava-kava and anxiety: growing knowledge about the efficacy and safety.Life Sci.2002702581259712269386
   PubMed Web of Science ®Google Scholar
• SinghYN.SinghNN.Therapeutic potential of kava in the treatment of anxiety disorders.CNS Drugs.20021673174312383029
   PubMed Web of Science ®Google Scholar
• IzzoAA.ErnstE.Interactions between herbal medicines and prescribed drugs: a systematic review.Drugs.2001612163217511772128
   PubMed Web of Science ®Google Scholar
• ErnstE.Harmless herbs? A review of the recent literature.Am J Med.19981041701789528737
   PubMed Web of Science ®Google Scholar
• Hepatic toxicity possibly associated with kava-containing products - United States, Germany and Switzerland.MMWR Mo it Mortal VVklyRep.20025110651067
   PubMedGoogle Scholar
• BallengerJC.Treatment of anxiety disorders to remission.J Clin Psychiatry.200162(suppl 12)5911430617
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.ShaderRl.Benzodiazepines in Clinical Practice. New York, NY: Raven Press;.1974
   Google Scholar
• BatesonAN.Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal.Current Pharm Design.20028521
   PubMed Web of Science ®Google Scholar
• MillerLG.Chronic benzodiazepine administration: from the patient to the gene.J Clin Pharmacol.1991314924951652596
   PubMed Web of Science ®Google Scholar
• MillerLG.GreenblattDJ.BarnhillJG.ShaderRl.Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased y-aminobutyric acidA receptor function.J Pharmacol Exp Ther.19882461701762839660
   PubMed Web of Science ®Google Scholar
• MillerLG.GreenblattDJ.RoyRB.SummerWR.ShaderRl.Chronic benzodiazepine administration. II. Discontinuation syndrome is associated with upregulation of y-aminobutyric acidA receptor complex binding and function.J Pharmacol Exp Ther.19882461771822455789
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.MillerLG.ShaderRl.Benzodiazepine discontinuation syndromes.J Psychiatr Res.199024(suppl 2)73791980702
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.ShaderRl.Pharmacokinetics of antianxiety agents In: Meltzer HY, ed.Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press;198713771386
   Google Scholar
• RickelsK.FoxIL.GreenblattDJ.SandlerKR.SchlessA.Clorazepate and lorazepam: clinical improvement and rebound anxiety.Am J Psychiatry.19881453123172894175
   PubMed Web of Science ®Google Scholar
• RickelsK.SchweizerE.CaseWG.GreenblattDJ.Long-term therapeutic use of benzodiazepines I. Effects of abrupt discontinuation.Arch Gen Psychiatry.1990478999072222129
   PubMed Web of Science ®Google Scholar
• SchweizerE.RickelsK.CaseWG.GreenblattDJ.Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper.Arch Gen Psychiatry.1990479089162222130
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.SethyVH.Benzodiazepine concentrations in brain directly reflect receptor occupancy: Studies of diazepam, lorazepam, and oxazepam.Psychopharmacology.19901023733781979181
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.EhrenbergBL.GundermanJ.et al.Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo.Clin Pharmacol Ther.1989453563652702793
   PubMed Web of Science ®Google Scholar
• RickelsK.DeMartinisN.RynnM.MandosL.Pharmacologic strategies for discontinuing benzodiazepine treatment.J Clin Psychopharrnacol.199919(6 suppl 2)12S16S
   Web of Science ®Google Scholar
• SpiegelDA.Psychological strategies for discontinuing benzodiazepine treatment.J Clin Psychopharrnacol.199919(6suppl2)17S22S
   Web of Science ®Google Scholar
• RickelsK.DeMartinisN.Garcia-EspanaF.GreenblattDJ.MandosLA.RynnM.Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy.Am J Psychiatry.20001571973197911097963
   PubMed Web of Science ®Google Scholar
• WestraHA.StewartSH.As-needed use of benzodiazepines in managing clinical anxiety: incidence and implications.Curr Pharm Design.200285974
   PubMed Web of Science ®Google Scholar
• PetrovicM.VandierendonckA.MarimanA.van MaeleG.AfschriftM.PevernagieD.Personality traits and socio-epidemiological status of hospitalised elderly benzodiazepine users.Int J Geriatr Psychiatry.20021773373812211123
   PubMed Web of Science ®Google Scholar
• FarrellM.HowesS.TaylorC.et al.Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey.Addict Behav.1998239099189801725
   PubMed Web of Science ®Google Scholar
• KandelDB.HuangFY.DaviesM.Comorbidity between patterns of substance use dependence and psychiatric syndromes.Drug Alcohol Depend.20016423324111543993
   PubMed Web of Science ®Google Scholar
• ConwayKP.SwendsenJD.RounsavilleBJ.MerikangasKR.Personality, drug of choice, and comorbid psychopathology among substance abusers.Drug Alcohol Depend.20026522523411841894
   PubMed Web of Science ®Google Scholar
• BurnsL.TeessonM.Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National Survey of Mental Health and Well-being.Drug Alcohol Depend.20026829930712393224
   PubMed Web of Science ®Google Scholar
• SchneiderU.AltmannA.BaumannM.et al.Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: the first multicenter study in Germany.Alcohol Alcohol.20013621922311373258
   PubMed Web of Science ®Google Scholar
• KanCC.BretelerMH.van der VenAH.et al.Assessment of benzodiazepine dependence in alcohol and drug dependent outpatients: a research report.Subst Use Misuse.2001361085109611504154
   PubMed Web of Science ®Google Scholar
• RossJ.DarkeS.The nature of benzodiazepine dependence among heroin users in Sydney, Australia.Addiction.2000951785179311177494
   PubMed Web of Science ®Google Scholar
• BeconaE.VazquezFL.MiguezMC.Smoking cessation and anxiety in a clinical sample.Personality individual Differences.200232489494
   Web of Science ®Google Scholar
• SchuckitMA.HesselbrockV.Alcohol dependence and anxiety disorders: what is the relationship?.Am J Psychiatry.19941511723347977877
   PubMed Web of Science ®Google Scholar
• KushnerMG.Relationship between alcohol problems and anxiety disorders.Am J Psychiatry.19961531391408540583
   PubMed Web of Science ®Google Scholar
• PosternakMA.MuellerTl.Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence.Am J Addict.200110486811268828
   PubMed Web of Science ®Google Scholar
• BarbeyJT.RooseSP.SSRI safety in overdose.J Clin Psychiatry.199859(suppl 15)42489786310
   PubMed Web of Science ®Google Scholar
• HaddadPM.Antidepressant discontinuation syndromes.Drug Safety.20012418319711347722
   PubMed Web of Science ®Google Scholar
• HaddadP.The SSRI discontinuation syndrome.J Psychopharrnacol.199812305313
   PubMed Web of Science ®Google Scholar
• SchatzberAF.HaddadP.KaplanEM.et al.Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel.J Clin Psychiatry.199758(suppl 7)510
   PubMed Web of Science ®Google Scholar
• MarkowitzJS.DeVaneCL.ListonHL.MontgomerySA.An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.Int Clin Psychopharrnacol.200015329333
   PubMed Web of Science ®Google Scholar
• TamamL.OzpoyrazN.Selective serotonin reuptake inhibitor discontinuation syndrome: a review.Adv Ther.200219172612008858
   PubMed Web of Science ®Google Scholar
• JudgeR.ParryMG.QuailD.JacobsonJG.Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.Int Clin Psychopharrnacol.200217217225
   PubMed Web of Science ®Google Scholar
• UhlenhuthEH.BaiterMB.BanTA.YangK.International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications. IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders.J Clin Psychopharrnacol.199919(6 suppl 2) 23S29S
   Web of Science ®Google Scholar
• BrauerHR.NowickiPW.CatalaneG.CatalaneMC.Panic attacks associated with citalopram.South Medj.20029510881089
   Google Scholar
• CatalanoG.HakalaSM.CatalaneMC.Sertraline-induced panic attacks.Clin Neuropharmacol.20002316416810895401
   PubMed Web of Science ®Google Scholar
• GreenblattDJ.von MoltkeLL.HarmatzJS.ShaderRl.Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.J Clin Psychopharrnacol.199919(5 suppl 1)23S35S
   Web of Science ®Google Scholar
• LiuB.AndersonG.MittmannN.et al.Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people,.Lancet.1998351130313079643791
   PubMed Web of Science ®Google Scholar
• ThapaPB.GideonP.CostTW.et al.Antidepressants and the risk of falls among nursing home residents.N Engl J Med.19983398758829744971
   PubMed Web of Science ®Google Scholar
• ArfkenCL.WilsonJG.AronsonSM.Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents.Int Psychogeriatr.200113859111352338
   PubMed Web of Science ®Google Scholar
• SleeperR.BondCA.Rojas-FernandezC.Psychotropic drugs and falls: new evidence pertaining to serotonin reuptake inhibitors.Pharmacotherapy.20002030831710730686
   PubMed Web of Science ®Google Scholar